Introduction: The Evolving Landscape of Adjuvant CDK4/6 Inhibition
In the management of high-risk, node-positive, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early-stage breast cancer (BC), the addition of abemaciclib to endocrine therapy (ET) has redefined the standard of care. This shift was primarily driven by the landmark monarchE trial, which demonstrated a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) for patients receiving the combination. However, the standard starting dose of abemaciclib—150 mg twice daily (b.i.d.)—presents a unique set of management challenges for clinicians and patients alike. The most notable barrier to long-term adherence is the drug’s toxicity profile, particularly gastrointestinal adverse events like diarrhea, which typically occur early in the treatment course.
Clinical experience suggests that the first few months of therapy are critical. Patients who experience significant toxicity during the initiation phase are at a higher risk of early treatment discontinuation, which may compromise the cumulative dose intensity required for optimal oncological outcomes. The TRADE trial (Tolerability of Abemaciclib Dose Escalation) was designed to address this unmet clinical need by investigating whether a structured, stepwise dose escalation could mitigate early toxicities and improve overall treatment persistence.
The Rationale for Dose Escalation: Physiological Adaptation
Abemaciclib is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Unlike other inhibitors in its class, abemaciclib has a distinct safety profile characterized by a high incidence of diarrhea (occurring in over 80% of patients in monarchE, though mostly Grade 1 or 2). The mechanism is thought to be related to the inhibition of CDK4/6 in the intestinal epithelium, which disrupts normal cell cycle progression in the gut mucosa.
There is emerging evidence that the gastrointestinal tract may undergo a form of physiological adaptation or ‘tachyphylaxis’ to CDK4/6 inhibition over time. By starting at a lower dose and gradually increasing to the target dose, clinicians hope to allow the gut mucosa to adapt, thereby reducing the peak intensity of early-onset diarrhea. This strategy has been successfully employed with other oncology drugs and chronic medications where initial side effects are transient but treatment-limiting.
Study Design: The TRADE Trial Protocol
The TRADE study was a prospective, single-arm, phase II clinical trial focused on the tolerability and feasibility of a dose-escalation schedule for adjuvant abemaciclib. The study enrolled 89 evaluable patients with high-risk, node-positive HR+/HER2- early breast cancer who were candidates for adjuvant therapy according to standard guidelines.
Dose Escalation Schedule
The intervention followed a clear, bi-weekly escalation protocol:
1. Weeks 1-2: 50 mg b.i.d.
2. Weeks 3-4: 100 mg b.i.d.
3. Week 5 onwards: Target dose of 150 mg b.i.d.
Escalation to the next dose level was conditional; it required the absence of ongoing Grade 3-4 toxicities or persistent Grade 2 toxicities. Patients who could not tolerate the escalation remained at their highest tolerated dose or underwent standard dose reductions as per clinical indications.
Primary Endpoint
The primary endpoint was a composite rate measured at 12 weeks, encompassing abemaciclib discontinuation for any reason OR the inability to reach/maintain the target dose of 150 mg b.i.d. The researchers compared this rate against a historical benchmark of 40%, derived from the monarchE trial data where patients started immediately at the 150 mg b.i.d. dose.
Key Findings: Significant Improvements in Tolerability
The TRADE trial successfully met its primary endpoint, demonstrating that the dose-escalation strategy significantly improved the composite tolerability rate at the 12-week mark.
The Composite Endpoint Analysis
Out of the 89 evaluable participants, 26 (29.2%) met the composite endpoint of failing to reach or maintain the target dose. This figure (90% CI: 21.3% to 38.2%) was statistically superior to the historical 40% failure rate (P = 0.023). A closer look at the 26 patients who met the endpoint reveals the following breakdown:
– 6.7% (n=6) discontinued the drug entirely within the first 12 weeks.
– 9.0% (n=8) were unable to reach the 150 mg dose during the escalation phase.
– 13.5% (n=12) reached 150 mg but required a subsequent dose reduction due to toxicity.
Crucially, 70.8% of the study population successfully reached and maintained the target dose of 150 mg b.i.d. through the first 12 weeks of therapy.
Safety and Discontinuation Rates
Perhaps the most striking result from the TRADE trial is the low rate of early discontinuation. In the monarchE trial, early discontinuation due to adverse events was a significant concern for clinicians. In TRADE, 93.3% of patients were still on abemaciclib therapy at the 12-week mark. This suggests that the dose-escalation approach provides a ‘buffer’ period, allowing patients and providers to manage side effects more effectively without abandoning the treatment altogether.
While the study was not powered to compare specific adverse event grades directly with monarchE, the qualitative feedback from the trial suggests that the gradual introduction of the drug made the initial onset of diarrhea more manageable. By the time patients reached the 150 mg dose, they were often already experienced in using anti-diarrheal medications (like loperamide) and had adjusted their dietary habits, leading to a more stable treatment experience.
Expert Commentary and Clinical Implications
The results of the TRADE trial offer a pragmatic solution to a frequent clinical dilemma. While oncologists strive for maximum dose intensity, the ‘real-world’ reality often involves patients who are hesitant to continue therapy if their quality of life is severely impacted in the first month of a multi-year regimen.
A New Standard for Initiation?
The TRADE strategy aligns with the broader movement toward personalized medicine and ‘patient-centric’ dosing. By validating a 50mg-100mg-150mg step-up approach, this study provides clinicians with an evidence-based framework to initiate abemaciclib. For patients who are particularly concerned about gastrointestinal side effects or those with baseline GI sensitivities, this escalation protocol may become the preferred method of starting treatment.
Efficacy Considerations
A common concern with dose escalation or reduction is whether it compromises the efficacy of the treatment. Post-hoc analyses of the monarchE trial have previously suggested that dose reductions (from 150 mg to 100 mg or even 50 mg) did not appear to diminish the IDFS benefit, provided the patient remained on the medication. The TRADE trial reinforces this concept by emphasizing persistence. A patient who stays on a slightly lower dose or takes longer to reach the target dose is likely to derive more benefit than a patient who discontinues therapy entirely within the first two months.
Limitations and Generalizability
As a single-arm phase II study, TRADE relies on historical comparisons rather than a concurrent randomized control group. Additionally, the 12-week endpoint focuses on the initiation phase; long-term follow-up will be necessary to ensure that these patients maintain adherence throughout the full two-year adjuvant course. However, given that most discontinuations occur early, the 12-week data is a highly relevant surrogate for long-term success.
Conclusion: A Practical Path Forward
The TRADE trial demonstrates that a structured dose-escalation strategy for adjuvant abemaciclib is both feasible and effective at improving early drug tolerability. By reducing the rate of early discontinuation and increasing the proportion of patients who can maintain the target dose, this protocol offers a refined approach to managing high-risk HR+/HER2- breast cancer. Clinicians should consider implementing this bi-weekly escalation schedule to optimize the patient experience and maximize the potential for long-term treatment success.
Funding and Clinical Trial Information
This study was supported by Eli Lilly and Company. The trial is registered at ClinicalTrials.gov (NCT04350138). Research was conducted across multiple academic and community oncology centers, reflecting a diverse patient population.
References
1. Mayer EL, Trapani D, Kim SE, et al. TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer. Ann Oncol. 2026;37(1):117-124. doi:10.1016/j.annonc.2025.09.141.
2. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1560-1570.
3. Rugo HS, O’Shaughnessy J, Boyle F, et al. Management of Adverse Events in Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors. The Oncologist. 2017;22(11):1305-1315.
